This PhD project is funded by the Faculty of Science for 3 years. Funding is available to UK/EU applicants and comprises home/EU tuition fees and an annual stipend of £15,009 for 3 years. Overseas applicants may apply but they are required to fund the difference between home/EU and overseas tuition fees (which for 2019-20 are detailed on the University’s fees pages at View Website . Please note tuition fees are subject to an annual increase).
1. Thomas A, Teicher BA, Hassa R (2016). Antibody drug conjugates for cancer therapy. Lancet Oncology 17, e254-e262.
2. Beekman AM, Cominetti MMD, Searcey M (2019). Duocarmycins as antibody-drug conjugate (ADC) payloads. Cytotoxic payloads for Antibody Drug Conjugates in RSC Drug Discovery Series, 71, 187-208.
3. Stephenson MJ et al (2015). Solid-phase synthesis of duocarmycin analogues and the effect of C-terminal substitution on biological activity. J. Org. Chem 80, 9454-9467.
4. Beekman AM, Cominetti MMD, Cartwright OC, Boger DL, Searcey M (2019). A small molecule drug conjugate (SMDC) of DUPA and a duocarmycin built on the solid phase MedChemComm 10, 2170-2174.